The new oral anticoagulants

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

(2009)   CIRCULATION

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans

(2009) D. Lang et al.   DRUG METABOLISM AND DISPOSITION

Editorial Board

(2009)   JOURNAL OF ARTHROPLASTY

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

(2009) JL Mega et al.   LANCET

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

(2009) Alexander GG Turpie et al.   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

(2008) H. R. Buller et al.   BLOOD

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

(2008) M. A. Crowther et al.   BLOOD

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

(2008) Ajay K Kakkar et al.   LANCET

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

(2008) Bengt I. Eriksson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

(2008) Michael R. Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE